Anti-cancer drug T-DM1 benefits women with advanced breast cancer who've failed previous treatments

(ECCO-the European CanCer Organisation) First results from a phase III clinical trial of the combination drug, T-DM1, show that it significantly improves the length of time before the disease worsens in women with advanced HER2 positive breast cancer whose cancer has recurred or progressed despite previous treatments, including trastuzumab and lapatinib. The research will be presented in a late-breaking presentation to the European Cancer Congress in Amsterdam.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news